TARS
Income statement / Annual
Last year (2023), Tarsus Pharmaceuticals, Inc.'s total revenue was $17.45 M,
a decrease of 32.42% from the previous year.
In 2023, Tarsus Pharmaceuticals, Inc.'s net income was -$135.89 M.
See Tarsus Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$17.45 M
|
$25.82 M
|
$57.03 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.59 M |
$955,000.00 |
$2.08 M |
$246,000.00 |
$74,000.00 |
$1,000.00 |
| Gross Profit |
$15.85 M |
$24.86 M |
$54.95 M |
-$246,000.00 |
-$74,000.00 |
-$1,000.00 |
| Gross Profit Ratio |
0.91 |
0.96 |
0.96 |
0 |
0 |
0 |
| Research and Development
Expenses |
$50.31 M
|
$42.62 M
|
$41.71 M
|
$18.83 M
|
$3.16 M
|
$901,000.00
|
| General & Administrative
Expenses |
$0.00
|
$44.95 M
|
$25.40 M
|
$8.17 M
|
$1.14 M
|
$449,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$108.70 M
|
$44.95 M
|
$25.40 M
|
$8.17 M
|
$1.14 M
|
$449,000.00
|
| Other Expenses |
$0.00 |
$86,000.00 |
-$73,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$159.01 M |
$87.57 M |
$67.11 M |
$27.00 M |
$4.30 M |
$1.35 M |
| Cost And Expenses |
$160.61 M |
$88.53 M |
$69.18 M |
$27.00 M |
$4.30 M |
$1.35 M |
| Interest Income |
$10.34 M |
$3.50 M |
$36,000.00 |
$188,000.00 |
$40,000.00 |
$0.00 |
| Interest Expense |
$3.35 M |
$2.20 M |
$0.00 |
$188,000.00 |
$40,000.00 |
$0.00 |
| Depreciation &
Amortization |
$877,000.00
|
$789,000.00
|
$606,000.00
|
$246,000.00
|
$74,000.00
|
$1,000.00
|
| EBITDA |
-$131.67 M
|
-$59.11 M
|
-$13.17 M
|
-$26.56 M
|
-$4.56 M
|
-$1.35 M
|
| EBITDA Ratio |
-7.55 |
-2.29 |
-0.19 |
0 |
0 |
0 |
| Operating Income Ratio
|
-8.21
|
-2.43
|
-0.21
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$7.27 M
|
$617,000.00
|
-$1.62 M
|
$188,000.00
|
-$371,000.00
|
$32,000.00
|
| Income Before Tax |
-$135.89 M |
-$62.10 M |
-$13.77 M |
-$26.81 M |
-$4.67 M |
-$1.32 M |
| Income Before Tax Ratio
|
-7.79
|
-2.41
|
-0.24
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$4,000.00 |
$55,000.00 |
$1,000.00 |
$1,000.00 |
$1,000.00 |
| Net Income |
-$135.89 M |
-$62.09 M |
-$13.83 M |
-$26.81 M |
-$4.67 M |
-$1.32 M |
| Net Income Ratio |
-7.79 |
-2.41 |
-0.24 |
0 |
0 |
0 |
| EPS |
-4.62 |
-2.52 |
-0.67 |
-1.32 |
-0.24 |
-0.31 |
| EPS Diluted |
-4.62 |
-2.52 |
-0.67 |
-1.32 |
-0.24 |
-0.31 |
| Weighted Average Shares
Out |
$29.38 M
|
$24.62 M
|
$20.55 M
|
$20.32 M
|
$19.51 M
|
$4.29 M
|
| Weighted Average Shares
Out Diluted |
$29.38 M
|
$24.62 M
|
$20.55 M
|
$20.32 M
|
$19.51 M
|
$4.29 M
|
| Link |
|
|
|
|
|
|
